RT Journal Article SR Electronic T1 Protecting people with multiple sclerosis through vaccination JF Practical Neurology JO Pract Neurol FD BMJ Publishing Group Ltd SP practneurol-2020-002527 DO 10.1136/practneurol-2020-002527 A1 Saúl Reyes A1 Mary Ramsay A1 Shamez Ladhani A1 Gayatri Amirthalingam A1 Neena Singh A1 Carlos Cores A1 Joela Mathews A1 Jonathan Lambourne A1 Monica Marta A1 Benjamin Turner A1 Sharmilee Gnanapavan A1 Ruth Dobson A1 Klaus Schmierer A1 Gavin Giovannoni YR 2020 UL http://pn.bmj.com/content/early/2020/07/05/practneurol-2020-002527.abstract AB Vaccines are key to preventing contagious, or serious, infections. However, their use in people with multiple sclerosis (pwMS) has often been problematic because of misguided concerns that vaccinations may exacerbate the disease and also because some disease-modifying therapies (DMTs) may influence the immune response to immunisations and/or their safety. PwMS may have higher morbidity and mortality from vaccine-preventable infections. It is, therefore, important to address any patient’s reluctance to accept vaccination and to provide clear guidance for clinicians on which vaccinations to consider proactively. We have reviewed the current literature and provide recommendations regarding vaccines in adults with MS, including specific advice regarding vaccination safety in patients receiving—or going to receive—DMTs, vaccination during pregnancy, pretravel counselling and patient education. Our aim is to endorse vaccination as one of the most efficient methods for protecting pwMS from infections and to provide a framework to ensure vaccinations are safe and effective.